ESTRO 2024 - Abstract Book

S2470

Clinical - Urology

ESTRO 2024

11. Musoro JZ, Coens C, Fiteni F, et al: Minimally Important Differences for Interpreting EORTC QLQ C30 Scores in Patients With Advanced Breast Cancer. JNCI Cancer Spectr 3:pkz037, 2019

1947

Digital Poster

Prostate Cancer ultra-hypofractionation: HR-QOL of a single center cohort

Ilaria Bonavero 1 , Giuseppe Carlo Iorio 1 , Sara Bartoncini 1 , Elena Gallio 2 , Diego Bongiovanni 1 , Sara Gaspari 1 , Valeria Chiofalo 1 , Cristiano Grossi 1 , Fabio Menegatti 1 , Edoardo Gozzelino 1 , Erica Cuffini 1 , Giuliana Petruzzellis 1 , Marzia Cerrato 1 , Bruna Lo Zito 1 , Chiara Casale 1 , Francesca Catena 1 , Eulalie Joelle Tondji Ngassam 1 , Mario Levis 1 , Ramona Parise 1 , Umberto Ricardi 1 1 University of Turin, Department of Oncology, Turin, Italy. 2 University of Turin, Department of Medical Physics, Turin, Italy

Purpose/Objective:

Health-related quality of life (HRQOL) evaluation of ultra-hypofractionated RT for localised (low- to high-risk) prostate cancer (PCa).

Material/Methods:

This HRQOL analysis pertains to a single-center cohort of patients (pts) treated with LINAC-based VMAT ultra hypofractionation (42.7 Gy/7 fractions every other day; 15-19 days). The treatment was delivered with daily IGRT (Cone-Beam CT). No fiducials nor spacers were employed. The CTV – PTV margin was 7 mm (5 mm towards the rectum). The CTV was defined as the prostate only for low-risk (LR) pts. CTV included proximal seminal vesicles (SVs) in intermediate-risk PCa and distal SVs for high-risk pts (HR). Whole SVs were included in the case of cT3b. Hormonal therapy prescription (HT) was at the physician's discretion in unfavorable-intermediate PCa (UIR) and mandatory in HR. HRQOL up to 2-years from treatment was evaluated through the Italian short-form of the UCLA-Prostate Cancer Index (-PCI). This short-form is a self-administered 14-item questionnaire that quantifies prostate-specific HRQOL in six domains: urinary function (UF) and bother (UB), bowel function (BF) and bother (BB), and sexual function (SF) and bother (SB). The scales are scored from 0 to 100, with higher scores representing better health states. The questionnaire was administered at baseline, RT end, 1-month (mo), 3-mos, 6-mos,12-mos, 18- and 24 mos from the end of RT. Moreover, IPSS scores (≤12 or >12) and genitourinary (GU)/gastrointestinal (GI) RTOG toxicity, both acute (within 3 mos) and late (≥ 6 mos), were simultaneously recorded to address a complete tolerance evaluation.

Results:

266 pts were treated between May 2020 and June 2023. The median age of the population was 75 years. Pts with a full 2-years follow-up were 84 (32%); while pts observed at least 1-year were 166 (62%), 215 at 6-mos (81%) and 244